Medicine composition of alpha-glucosidase inhibitor and vitamin B

A technology of glucosidase and composition, applied in the field of pharmacy, can solve problems such as early prevention and treatment of diabetic complications, vascular disease complications, etc.

Inactive Publication Date: 2013-08-07
SHENZHEN AUSA PHARMA
View PDF5 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] The therapeutic drugs for diabetes on the market are mainly hypoglycemic drugs with different mechanisms of action. They pay attention to correcting the abnormal blood sugar and meta

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine composition of alpha-glucosidase inhibitor and vitamin B
  • Medicine composition of alpha-glucosidase inhibitor and vitamin B
  • Medicine composition of alpha-glucosidase inhibitor and vitamin B

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0042] Example 1 Preparation of Compound Acarbose / Folic Acid Tablets (1000 Tablets)

[0043] formula:

[0044]

[0045] Preparation method: pass the raw and auxiliary materials through a 80-mesh sieve, and dry for later use. Take the prescribed amount of folic acid and acarbose and mix them uniformly according to the method of equal increase, weigh the prescribed amount of microcrystalline cellulose, low-substituted hydroxypropyl cellulose (L-HPC), sodium carboxymethyl starch, and mix them with the raw materials The powder is fully mixed according to the method of equal increase, and an appropriate amount of 5% povidone 95% ethanol solution is added to make a soft material, granulated with a 20-mesh sieve, dried at 50°C for about 6 hours, and granulated with a 20-mesh sieve to control the water content of the granules. 2-3%, the dried granules are uniformly mixed with the prescribed amount of magnesium stearate, the intermediate is tested, and pressed into 1000 tablets. ...

Embodiment 2

[0046] Example 2 Preparation of Compound Voglibose / Folic Acid Tablets (1000 Tablets)

[0047] formula:

[0048] Preparation method: pass the raw and auxiliary materials through a 80-mesh sieve, and dry for later use. Take the prescribed amount of folic acid and voglibose and mix them uniformly according to the method of equal increase, weigh the prescribed amount of microcrystalline cellulose, lactose, cross-linked polyvinylpyrrolidone, sodium carboxymethyl starch, and mix them with the raw material medicine in an equal amount Mix well by incremental method, add appropriate amount of 10% starch slurry solution to make soft material, granulate with 20-mesh sieve, dry at 50°C for about 6 hours, granulate with 20-mesh sieve, control the water content of the granules to 2-3%. The granules are uniformly mixed with the prescription amount of glyceryl behenate and magnesium stearate, the intermediate is tested, and pressed into 1000 tablets. Pay attention to avoiding light during...

Embodiment 3

[0049] Example 3 Preparation of Compound Miglitol / 5-Methyltetrahydrofolic Acid Tablets (1000 Tablets)

[0050] formula:

[0051]

[0052] Preparation method: the auxiliary material is a direct pressing auxiliary material, which is dried for later use. Take the prescribed amount of 5-methyltetrahydrofolate and 10 g of microcrystalline cellulose and mix uniformly according to the method of equal increase to obtain the powder mixing intermediate 1; weigh the remaining microcrystalline cellulose, lactose, and sodium carboxymethyl starch in the prescribed amount , and Miglitol are fully mixed according to the method of equal increments to obtain the powder-mixing intermediate 2; the powder-mixing intermediate 1 and the powder-mixing intermediate 2 are mixed with the prescription amount of magnesium stearate according to the method of equal increments, Obtain the final mixed powder intermediate, detect the mixed powder intermediate, and press into 1000 pieces. Pay attention t...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a medicine composition composed of one of a pharmaceutically acceptable dose of alpha-glucosidase inhibitor and active metabolite of salt thereof, one or more of pharmaceutically acceptable doses of vitamin B, and a pharmaceutically acceptable carrier. The invention belongs to the field of medicine. The invention also relates to an application of the composition in preparing diabetes-treating medicines. With a medicine prepared by using the medicine composition provided by the invention, blood sugar can be effectively reduced, and a beneficial effect of substantially controlling diabetes vascular lesion complications is provided. Therefore, the medicine is a more appropriate anti-diabetic medicine.

Description

technical field [0001] The present invention relates to one of the α-glucosidase inhibitor hypoglycemic drugs and their active metabolites or salts, one or more B vitamins in a medicinal dosage and a pharmaceutically acceptable carrier. The pharmaceutical composition and the application of the composition in the preparation of medicines for treating diabetes and its complications. The present invention belongs to the field of pharmacy. Background technique [0002] Diabetes mellitus is a common endocrine and metabolic disease characterized by chronic hyperglycemia accompanied by disturbances in sugar, fat and protein metabolism caused by insufficient insulin secretion and / or action defects. According to epidemiological surveys, the prevalence of diabetes in my country is as high as 9.7% (Yang W, et al. Nearly 100 million people. Therefore, diabetes has become a serious public health problem. Vascular complications often occur with the progression of diabetes, including ma...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/519A61K31/7036A61P13/12A61P9/14A61K31/714A61K31/133A61K31/4415A61K45/06A61P9/10A61P3/10A61K31/445
Inventor 张磊王滨燕陈光亮王存芳徐希平徐欣于多王文艳
Owner SHENZHEN AUSA PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap